
Marten Trendelenburg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/974717/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum interferon- $\hat{1}\pm$ levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. Annals of the Rheumatic Diseases, 2022, 81, 901-903.	0.5	11
2	Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin necrosis. Clinics in Dermatology, 2022, 40, 397-401.	0.8	9
3	Prediction of Acute COPD Exacerbation in the Swiss Multicenter COPD Cohort Study (TOPDOCS) by Clinical Parameters, Medication Use, and Immunological Biomarkers. Respiration, 2022, 101, 441-454.	1.2	4
4	Perception of physicians and nursing staff members regarding outside versus bedside ward rounds: ancillary analysis of the randomised BEDSIDE-OUTSIDE trial Swiss Medical Weekly, 2022, 152, w30112.	0.8	0
5	Anti-C1q Autoantibodies: Standard Quantification and Innovative ELISA. Methods in Molecular Biology, 2021, 2227, 107-114.	0.4	4
6	Autoantibodies against complement component C1q in systemic lupus erythematosus. Clinical and Translational Immunology, 2021, 10, e1279.	1.7	15
7	Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial. Respiratory Research, 2021, 22, 227.	1.4	3
8	Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. Genes, 2021, 12, 1268.	1.0	0
9	Effect of Bedside Compared With Outside the Room Patient Case Presentation on Patients' Knowledge About Their Medical Care. Annals of Internal Medicine, 2021, 174, 1282-1292.	2.0	13
10	Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials, 2021, 22, 1.	0.7	81
11	Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study. Frontiers in Immunology, 2021, 12, 765330.	2.2	15
12	Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 761395.	2.2	5
13	Preclinical to clinical translation of cenerimod, a novel S1P ₁ receptor modulator, in systemic lupus erythematosus. RMD Open, 2020, 6, e001261.	1.8	10
14	Complement C1q Enhances Primary Hemostasis. Frontiers in Immunology, 2020, 11, 1522.	2.2	13
15	Case Report—Secondary Antibody Deficiency Due to Endogenous Hypercortisolism. Frontiers in Immunology, 2020, 11, 1435.	2.2	3
16	Local and Systemic Concentrations of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases. Frontiers in Immunology, 2020, 11, 562564.	2.2	8
17	P138â€Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE. , 2020, , .		1
18	O38â€Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE. , 2020, , .		0

#	Article	IF	CITATIONS
19	P16â€The combined type-I interferon and neutrophil gene scores identify highly active systemic lupus erythematosus patients and performed better than classical serological markers. , 2020, , .		0
20	Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System. Frontiers in Immunology, 2020, 11, 2072.	2.2	67
21	Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers. Rheumatology, 2020, 59, 3468-3478.	0.9	18
22	A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced KidneyÂlnjury. JACC: Cardiovascular Interventions, 2020, 13, 833-842.	1.1	10
23	No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic Lupus Erythematosus. Scientific Reports, 2020, 10, 3693.	1.6	4
24	Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus. Rheumatology, 2019, 59, 534-544.	0.9	3
25	SaO039RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (CONESTAT ALFA) IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN HIGH-RISK PATIENTS (PROTECT): A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND SINGLE-CENTER TRIAL. Nephrology Dialysis Transplantation, 2019, 34	0.4	0
26	Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus. Journal of Clinical Immunology, 2019, 39, 421-429.	2.0	28
27	Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. Arthritis Research and Therapy, 2019, 21, 76.	1.6	10
28	Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrology, 2019, 20, 430.	0.8	11
29	Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site. Frontiers in Immunology, 2019, 10, 2619.	2.2	22
30	Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages. Frontiers in Immunology, 2019, 10, 2712.	2.2	13
31	Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology, 2019, 58, 908-913.	0.9	19
32	Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus. Rheumatology, 2018, 57, 1350-1357.	0.9	28
33	Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 348-357.	0.4	7
34	Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. Nephrology Dialysis Transplantation, 2018, 33, 54-64.	0.4	12
35	The heart in systemic lupus erythematosus – A comprehensive approach by cardiovascular magnetic resonance tomography. PLoS ONE, 2018, 13, e0202105.	1.1	39
36	Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 2090.	2.2	16

#	Article	IF	CITATIONS
37	The Lectin Pathway of Complement in Myocardial Ischemia/Reperfusion Injury—Review of Its Significance and the Potential Impact of Therapeutic Interference by C1 Esterase Inhibitor. Frontiers in Immunology, 2018, 9, 1151.	2.2	39
38	The Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1136-1144.	1.0	36
39	Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. PLoS ONE, 2018, 13, e0188695.	1.1	12
40	Association of Lectin Pathway Protein Levels and Genetic Variants Early after Injury with Outcomes after Severe Traumatic Brain Injury: A Prospective Cohort Study. Journal of Neurotrauma, 2017, 34, 2560-2566.	1.7	18
41	Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages. Biochemical Pharmacology, 2017, 146, 151-164.	2.0	26
42	Primary intestinal lymphangiectasia in an elderly female patient. Medicine (United States), 2017, 96, e7729.	0.4	9
43	Association of lectin pathway protein levels and genetic variants early after injury with outcomes after severe traumatic brain injury. A prospective cohort study. Molecular Immunology, 2017, 89, 212-213.	1.0	Ο
44	Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunology, 2017, 18, 17.	0.9	42
45	Anti-C1q autoantibodies from patients with systemic lupus erythematosus induce C1q production by macrophages. Journal of Leukocyte Biology, 2017, 101, 481-491.	1.5	10
46	TOO11BAFF AND IMMUNE COMPLEXES CONSISTING OF BAFF AND IMMUNOGLOBULIN G ARE ASSOCIATED WITH RENAL INVOLVEMENT AND DISEASE ACTIVITY IN SLE. Nephrology Dialysis Transplantation, 2017, 32, iii82-iii82.	0.4	0
47	A prediction model for exacerbations in patients with COPD generated in a Swiss multicenter COPD cohort study (TOPDOCS). , 2017, , .		Ο
48	Anti-C1q autoantibodies are linked to autoimmune thyroid disorders in pregnant women. Clinical and Experimental Immunology, 2016, 186, 10-17.	1.1	4
49	Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. Journal of Immunology, 2016, 197, 3669-3679.	0.4	25
50	Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland. Journal of Infection, 2016, 72, 377-385.	1.7	6
51	Anti-C1q Autoantibodies from Systemic Lupus Erythematosus Patients Induce a Proinflammatory Phenotype in Macrophages. Journal of Immunology, 2016, 196, 2063-2074.	0.4	28
52	Interferon-lambda-genotype GG and IgG2 are predictors for frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS). , 2016, , .		0
53	FRI0390â€Health-Related Quality of Life in Swiss Patients with Systemic Lupus Erythematosus – A Cross-Sectional Analysis Within the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). Annals of the Rheumatic Diseases, 2015, 74, 568.2-568.	0.5	0
54	Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. Respiratory Research, 2015, 16, 150.	1.4	18

MARTEN TRENDELENBURG

#	Article	IF	CITATIONS
55	Anti-C1q Antibodies as a Follow-Up Marker in SLE Patients. PLoS ONE, 2015, 10, e0123572.	1.1	49
56	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Research and Therapy, 2015, 17, 371.	1.6	20
57	Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: A cross-sectional study of two cohorts. Lupus, 2015, 24, 58-65.	0.8	21
58	Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways. Clinical Immunology, 2015, 160, 180-187.	1.4	33
59	Clinical presentation of human C1q deficiency: How much of a lupus?. Molecular Immunology, 2015, 67, 3-11.	1.0	86
60	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	1.1	54
61	The Swiss Systemic lupus erythematosus Cohort Study (SSCS) – cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Medical Weekly, 2014, 144, w13990.	0.8	31
62	Critical incidents in a tertiary care clinic for internal medicine. BMC Research Notes, 2013, 6, 276.	0.6	13
63	Anti-C1q antibodies as a follow-up marker in SLE patients. Molecular Immunology, 2013, 56, 274.	1.0	Ο
64	Impact of Mannose-Binding Lectin Deficiency on Radiocontrast-Induced Renal Dysfunction. BioMed Research International, 2013, 2013, 1-8.	0.9	6
65	Association between Low Levels of Mannan-Binding Lectin and Markers of Autoimmune Thyroid Disease in Pregnancy. PLoS ONE, 2013, 8, e81755.	1.1	3
66	Low Levels of Mannan-Binding Lectin or Ficolins Are Not Associated with an Increased Risk of Cytomegalovirus Disease in HIV-Infected Patients. PLoS ONE, 2013, 8, e51983.	1.1	8
67	A Trial of Complement Inhibition in a Patient with Cryoglobulin-Induced Glomerulonephritis. Case Reports in Nephrology and Urology, 2012, 2, 38-45.	1.5	6
68	Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti 1q antibodies by a specific peptideâ€based enzymeâ€linked immunosorbent assay. Arthritis and Rheumatism, 2012, 64, 3706-3714.	6.7	37
69	Identification of critical core amino acids of a major linear C1q epitope recognized by SLE auto-antibodies. Immunobiology, 2012, 217, 1176.	0.8	1
70	Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. BMC Nephrology, 2012, 13, 99.	0.8	4
71	Serum cytokine profile in patients with active lupus nephritis. Cytokine, 2012, 60, 410-416.	1.4	76
72	MBL serum levels in patients with sepsis correlate with thyroid function but not with outcome. Clinical Immunology, 2012, 144, 80-82.	1.4	5

#	Article	IF	CITATIONS
73	Anti-C1q antibodies as a diagnostic marker of proliferative lupus nephritis: Comment on the article by Katsumata et al. Arthritis and Rheumatism, 2012, 64, 324-325.	6.7	3
74	Cryoglobulinemia and Chronic HCV Infection: An Evolving Story. , 2012, , 79-83.		0
75	The Complement System in Cryoglobulinemia. , 2012, , 85-89.		Ο
76	Mannose-binding lectin—the forgotten molecule?. Nature Medicine, 2011, 17, 1547-1548.	15.2	7
77	Mannose-Binding Lectin Deficiency Is Associated With Smaller Infarction Size and Favorable Outcome in Ischemic Stroke Patients. PLoS ONE, 2011, 6, e21338.	1.1	77
78	The role of functional Mannose-binding lectin deficiency in contrast-induced nephropathy. Molecular Immunology, 2011, 48, 1717-1718.	1.0	0
79	Identification of epitopes on the collagen-like region of C1q recognized by serum antibodies from patients with lupus erythematosus. Molecular Immunology, 2011, 48, 1720-1721.	1.0	0
80	Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. Nephrology Dialysis Transplantation, 2011, 26, 1220-1228.	0.4	20
81	Three cases of primary small vessel vasculitis of the skeletal muscle-an own entity. BMJ Case Reports, 2011, 2011, bcr0820114631-bcr0820114631.	0.2	8
82	Mannose-binding lectin levels and major infections in a cohort of very long-term survivors after allogeneic stem cell transplantation. Haematologica, 2010, 95, 1389-1396.	1.7	15
83	Primary cytomegalovirus infection with accompanying Pneumocystis jiroveci pneumonia in a patient with large-vessel vasculitis. Infection, 2010, 38, 331-334.	2.3	9
84	Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. Molecular Immunology, 2010, 47, 2208-2208.	1.0	0
85	The production of mannan-binding lectin is dependent upon thyroid hormones regardless of the genotype: A cohort study of 95 patients with autoimmune thyroid disorders. Clinical Immunology, 2010, 136, 123-129.	1.4	20
86	A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13. Nephrology Dialysis Transplantation, 2010, 25, 1720-1722.	0.4	8
87	Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal, 2010, 31, 1181-1187.	1.0	53
88	Autoantibodies against Complement C1q Specifically Target C1q Bound on Early Apoptotic Cells. Journal of Immunology, 2009, 183, 3512-3521.	0.4	67
89	Autoantibodies against C1q in Systemic Lupus Erythematosus Are Antigen-Driven. Journal of Immunology, 2009, 183, 8225-8231.	0.4	50
90	Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Clinical and Experimental Immunology, 2008, 153, 96-101.	1.1	22

#	Article	IF	CITATIONS
91	Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clinical Immunology, 2008, 128, 409-414.	1.4	21
92	Antinucleosome Antibodies as a Marker of Active Proliferative Lupus Nephritis. American Journal of Kidney Diseases, 2008, 51, 624-629.	2.1	44
93	Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. Molecular Immunology, 2008, 45, 4118.	1.0	1
94	Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Molecular Immunology, 2008, 45, 4174.	1.0	0
95	Acute Liver Failure in Two Patients with Regular Alcohol Consumption Ingesting Paracetamol at Therapeutic Dosage. Digestion, 2007, 75, 232-237.	1.2	22
96	Rituximab in a Patient With Hyper-IgE Syndrome. Archives of Dermatology, 2007, 143, 799.	1.7	7
97	Association Between Mannose-Binding Lectin Deficiency and Cytomegalovirus Infection After Kidney Transplantation. Transplantation, 2007, 83, 359-362.	0.5	81
98	Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. Transplant Infectious Disease, 2007, 9, 214-218.	0.7	9
99	Complement inhibition by anti-C5 antibodiesfrom bench to bedside and back again. Swiss Medical Weekly, 2007, 137, 413-7.	0.8	5
100	Anti-C1q antibodies in hepatitis C virus infection. Clinical and Experimental Immunology, 2006, 145, 308-312.	1.1	43
101	High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrology Dialysis Transplantation, 2006, 21, 3115-3121.	0.4	164
102	Clinical Value of Autoantibodies Against C1q in Children With Glomerulonephritis. Pediatrics, 2006, 117, 1663-1668.	1.0	35
103	Antibodies against C1q in patients with systemic lupus erythematosus. Seminars in Immunopathology, 2005, 27, 276-285.	4.0	81
104	The Role of Complement in Cryoglobulin-Induced Immune Complex Glomerulonephritis. Journal of Immunology, 2005, 175, 6909-6914.	0.4	57
105	Monocytosis and accelerated activation of lymphocytes in C1q-deficient autoimmune-prone mice. Immunology, 2004, 113, 80-88.	2.0	19
106	Autoantibodies against complement receptor 1 (CD35) in SLE, liver cirrhosis and HIV-infected patients. Clinical and Experimental Immunology, 2003, 131, 174-181.	1.1	11
107	Cryoglobulins in chronic hepatitis C virus infection. Clinical and Experimental Immunology, 2003, 133, 153-155.	1.1	29
108	Cryoglobulin/albumin complexes in a patient with severe autoimmune syndrome. Scandinavian Journal of Rheumatology, 2003, 32, 367-373.	0.6	6

#	Article	IF	CITATIONS
109	Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. American Journal of Kidney Diseases, 2001, 37, 490-498.	2.1	168
110	Disseminated scabies evolving in a patient undergoing induction chemotherapy for acute myeloblastic leukaemia. Annals of Hematology, 2001, 80, 116-118.	0.8	2
111	â€~Altered immunity syndrome', a distinct entity in long-term bone marrow transplantation survivors?. Bone Marrow Transplantation, 2001, 28, 1175-1176.	1.3	15
112	Hepatitis Virus-Related and Ethanol-Induced Chronic Liver Disease with or without Cryoglobulins - Is There a Difference Concerning Clinical or Laboratory Manifestation?. Infection, 1999, 27, 248-251.	2.3	5
113	Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis and Rheumatism, 1999, 42, 187-188.	6.7	121
114	Hypocomplementemic urticarial vasculitis or systemic lupus erythematosus?. American Journal of Kidney Diseases, 1999, 34, 745-751.	2.1	42
115	Cryoglobulins are not essential. Annals of the Rheumatic Diseases, 1998, 57, 3-5.	0.5	41
116	A New Steroid-Eluting Screw-In Electrode. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 1134-1142.	0.5	20